Cucumber products in DC, MD & VA recalled over possible salmonella contamination
WASHINGTON - The Coastal Companies has announced a voluntary recall of 17 products containing cucumbers due to potential salmonella contamination, the U.S. Food and Drug Administration announced.
The affected cucumbers, grown by Bedner Growers, Inc., were distributed between May 6 and May 21, 2025, to customers in Washington, D.C., Maryland, Virginia, Ohio, Michigan, West Virginia, Delaware, Massachusetts, Pennsylvania, New Jersey, Vermont, and North Carolina.
The recall includes salads, salsas, and other items made with fresh cucumbers. Consumers and retailers are urged to check their inventory and discard any impacted products.
What we know
The following products are being recalled. All lot codes of the items listed below are affected.
UPC: 640344010282Pack Size: 1/16 ozBrand: East Coast FreshDescription: Fresh Mild Salsa
UPC: 640344012781Pack Size: 1/16 ozBrand: East Coast FreshDescription: Fresh Mild Salsa
UPC: 070784034140Pack Size: 1/16 ozBrand: TOPSDescription: Salsa HOT TOPS (E)
UPC: 070784033846Pack Size: 1/16 ozBrand: TOPSDescription: Fresh Salsa 1lb CUP
UPC: 888670065808Pack Size: 1/30 ozBrand: Wellsley FarmsDescription: Wellsley Farms Mild Salsa
UPC: 041497075959Pack Size: 1/16 ozBrand: WEISDescription: Salsa Mild WEIS
UPC: 688267031953Pack Size: 1/16 ozBrand: AHOLDDescription: Salsa HOT AHOLD
UPC: 688267032523Pack Size: 1/16 ozBrand: AHOLDDescription: Salsa 1#-AHOLD
UPC: 640344069624Pack Size: 1/16 ozBrand: East Coast FreshDescription: SALSA RETAIL 1# CUP
UPC: 766375251385Pack Size: 1/8 ozBrand: Jack and OliveDescription: The House Salad
UPC: 766375241973Pack Size: 1/8 ozBrand: Created FreshDescription: The House Salad
UPC: 766375737018Pack Size: 1/8 ozBrand: Spring and SproutDescription: The House Salad
UPC: 766375241607Pack Size: 1/5.2 ozBrand: Created FreshDescription: Mini Garden Salad
UPC: 766375261681Pack Size: 1/5.76 ozBrand: Created FreshDescription: Chicken Salad on Everything Fecelle
UPC: 766375261698Pack Size: 1/5.76 ozBrand: Created FreshDescription: Egg Salad on Everything Fecelle
UPC: 766375261674Pack Size: 1/5.76 ozBrand: Created FreshDescription: Tuna Salad on Everything Fecelle
UPC: 766375253044Pack Size: 1/11.25 ozBrand: Created FreshDescription: Southwestern Breakfast Bowl
FDA officials have linked the recalled cucumbers from Bedner's Farm to 26 reported illnesses across 15 states. Officials confirmed that no other products distributed by The Coastal Companies are affected by the recall. The company is working with the FDA on the matter, they said.
The FDA says consumers, restaurants, retailers, and wholesalers should dispose of any potentially contaminated cucumbers. If it is unclear whether a product contains the affected cucumbers, officials recommend discarding it as a precaution.
READ THE ENTIRE RECALL ALERT ONLINE
The Source
Information in this article comes from the U.S. Food and Drug Administration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Fresenius Medical starts US commercialisation of haemodiafiltration system
Fresenius Medical Care (FME) has commenced the US commercialisation of its high-volume haemodiafiltration (HVHDF) kidney replacement therapy, 5008X CAREsystem. The full-scale commercial launch is anticipated by the company in 2026. FME secured the Food and Drug Administration's (FDA) 510(k) clearance last week for the updated HDF-capable system. In February 2024, FME first obtained the clearance for the 5008X CAREsystem, enabling focused testing and clinical assessments. The latest clearance approves additional features, including the Fresenius Clinical Data Exchange (CDX), which facilitates ONE-TOUCH access to medical information systems, eliminating the need for extra computer stations. The CDX claims to optimise clinic workflows, mitigate cross-contamination risks, and reduce citations under the CMS V-tag by streamlining data access and freeing up the clinic area by minimising the cabling clutter. Over the coming months, FMS' Care Delivery patient care business segment will start providing HDF dialysis therapy in chosen first wave clinics within its US Fresenius Kidney Care dialysis clinics network. This gradual rollout will continue throughout the year. The 5008X CAREsystem, paired with the FDA-approved FX CorAL dialyser, represents a leap in medical device innovation by Fresenius. It not only enables HVHDF but also introduces enhancements in workflow and therapy. The CONVINCE study, funded by the EU and conducted across eight European countries, found that subjects undergoing HVHDF had a significant 23% reduction in death rates against those receiving high-flux haemodialysis. FME CEO Helen Giza said: 'Last week's FDA clearance of our updated 5008X CAREsystem with additional features was a critical milestone in our work to improve the lives of people living with kidney disease by bringing industry-leading, HVHDF dialysis therapy to the US. 'Haemodiafiltration is already the treatment standard across much of Europe, Latin America, and Asia, and we are very well experienced with it. Our great familiarity with this treatment, combined with the outcome and promising results of the external CONVINCE research study, reiterated the significant patient health and well-being benefits available with HVHDF.' "Fresenius Medical starts US commercialisation of haemodiafiltration system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
2 hours ago
- Yahoo
1 Mooning Stock with Solid Fundamentals and 2 to Keep Off Your Radar
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. While momentum can be a leading indicator, it has burned many investors as it doesn't always correlate with long-term success. All that said, here is one stock with the fundamentals to back up its performance and two not so much. One-Month Return: +69.6% Known for constructing the Philadelphia Eagles' Stadium, Tutor Perini (NYSE:TPC) is a civil and building construction company offering diversified general contracting and design-build services. Why Does TPC Give Us Pause? Sales stagnated over the last five years and signal the need for new growth strategies High input costs result in an inferior gross margin of 6.1% that must be offset through higher volumes Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions Tutor Perini's stock price of $38.61 implies a valuation ratio of 18.5x forward P/E. If you're considering TPC for your portfolio, see our FREE research report to learn more. One-Month Return: +3.1% With over 600 million tests performed annually and involvement in 90% of FDA-approved drugs in 2023, Labcorp (NYSE:LH) provides laboratory testing services and drug development solutions to doctors, hospitals, pharmaceutical companies, and patients worldwide. Why Does LH Worry Us? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 13.3 percentage points Eroding returns on capital suggest its historical profit centers are aging At $254.37 per share, Labcorp trades at 15.4x forward P/E. Check out our free in-depth research report to learn more about why LH doesn't pass our bar. One-Month Return: +31.5% Founded as a purveyor of vintage items, Urban Outfitters (NASDAQ:URBN) now largely sells new apparel and accessories to teens and young adults seeking on-trend fashion. Why Do We Watch URBN? Locations open for at least a year are seeing increased demand as same-store sales have averaged 4.2% growth over the past two years Projected revenue growth of 8% for the next 12 months indicates demand will rise above its six-year trend Earnings per share grew by 46.7% annually over the last five years and trumped its peers Urban Outfitters is trading at $70.60 per share, or 15.8x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today for free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
2 hours ago
- Medscape
AI Device Enhances Skin Cancer Diagnosis in Primary Care
An artificial intelligence (AI)–enabled handheld elastic scattering spectroscopy (ESS) device improved the sensitivity for skin cancer diagnosis and management by primary care physicians (PCPs), with better overall diagnostic accuracy. METHODOLOGY: ESS is a sampling technique that distinguishes between benign and malignant tissue without surgical biopsy and the ESS device is cleared by the US Food and Drug Administration for use by nondermatologist expert physicians. An AI-enabled handheld ESS device was developed to aid PCPs in the management of suspicious skin lesions. This companion study of the DERM-SUCCESS study conducted across 22 primary care sites in the United States evaluated the impact of the device on PCPs' diagnostic performance in the detection and management of skin cancer. The study involved 108 PCPs (65.7% men) who assessed 50 skin lesion cases (25 benign and 25 malignant) from 50 patients (median age, 59 years; 100% White individuals) in two phases: First, with visual assessment without using the handheld device, followed by an assessment using the device, separated by a 2-hour break. For each lesion, they provided a diagnosis, management decision, and level of confidence in their assessment. The validated device emitted light pulses over specific areas of a lesion to analyze lesion structure and classified lesions as 'Investigate Further' or 'Monitor,' with a 1-10 score reflecting the degree of similarity to malignant lesions. The coprimary endpoints were (1) the referral sensitivity of physicians, a measurement of the ability to appropriately refer malignant cases for further evaluation (management sensitivity) and (2) the referral sensitivity and specificity of physicians who knew the device results. Biopsy results served as the reference standard for both. TAKEAWAY: Management sensitivity was higher for physicians after using the AI-enabled device compared with when they did not have the device results (91.4% vs 82%; P = .0027). PCPs' diagnostic sensitivity also increased from 71.1% without the use of the AI device to 81.7% with the use of the AI device ( P = .0085). = .0027). PCPs' diagnostic sensitivity also increased from 71.1% without the use of the AI device to 81.7% with the use of the AI device ( = .0085). Device-aided management and diagnostic specificity decreased, though not significantly. The use of the device led to 11.8% more benign lesions being incorrectly referred but also led to 9.4% more malignant lesions being correctly referred. In physician management decisions, the proportion of high-confidence assessments increased from 36.8% without the use of the device to 53.4% after the use of the device, and the observed area under the curve performance improved from 0.708 to 0.762. PCPs using the device were better at detecting malignant lesions than by chance (odds ratio, 6.8; P < .0001). Most PCPs reported benefits from the device, including improved confidence in clinical assessments and management decisions. IN PRACTICE: 'The findings demonstrate that utilization of the ESS device output may improve physician performance in the management of suspicious lesions and referral of skin cancer to ensure timely diagnosis,' the authors of the study wrote. SOURCE: This study was led by Laura K. Ferris, of the Department of Dermatology at The University of North Carolina at Chapel Hill. It was published online on May 30, 2025, in Journal of Primary Care & Community Health . LIMITATIONS: The device could not directly affect how PCPs managed lesions owing to the study design because the device was experimental. Clinical information was provided, but the PCPs could not perform hands-on evaluations, which did not reflect real clinical practice but aligned with telemedicine. The study included only White patients, which limited the results for the assessment of different skin types. DISCLOSURES: This study was funded by DermaSensor, Inc. The authors declared no relevant conflicts of interest.
